I-01 Andrijana Radivojevic Enhancing population PK modeling efficiency using an integrated workflow Wednesday 10:05-11:40 |
I-04 Philippe Jacqmin Constructing the disease trajectory of CDR-SOB in Alzheimer’s disease progression modelling Wednesday 10:05-11:40 |
I-07 Alberto Russu Second-order indirect response modelling of complex biomarker dynamics Wednesday 10:05-11:40 |
I-19 Alexander Solms Translating physiologically based Parameterization and Inter-Individual Variability into the Analysis of Population Pharmacokinetics Wednesday 10:05-11:40 |
I-22 Michael Spigarelli Title: Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses Wednesday 10:05-11:40 |
I-29 Elin Svensson Individualization of fixed-dose combination (FDC) regimens - methodology and application to pediatric tuberculosis Wednesday 10:05-11:40 |
I-31 Maciej Swat PharmML – An Exchange Standard for Models in Pharmacometrics Wednesday 10:05-11:40 |
I-51 Max von Kleist Systems Pharmacology of Chain-Terminating Nucleoside Analogs Wednesday 10:05-11:40 |
II-04 Thomas Dumortier Using a model-based approach to address FDA’s midcycle review concerns by demonstrating the contribution of everolimus to the efficacy of its combination with low exposure tacrolimus in liver transplantation Wednesday 14:50-16:20 |
II-12 Nicolas Frances A semi-physiologic mathematical model describing pharmacokinetic profile of an IgG monoclonal antibody mAbX after IV and SC administration in human FcRn transgenic mice. Wednesday 14:50-16:20 |
II-14 Ludivine Fronton A Novel PBPK Approach for mAbs and its Implications in the Interpretation of Classical Compartment Models Wednesday 14:50-16:20 |
II-22 Ekaterina Gibiansky Immunogenicity in PK of Monoclonal Antibodies: Detection and Unbiased Estimation of Model Parameters Wednesday 14:50-16:20 |
II-23 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): Simplification of Equations and Model-Independent Assessment of Deconjugation Rate Wednesday 14:50-16:20 |
II-29 Ignacio Gonzalez-Garcia Simultaneous Modelling Of Fexofenadine In In Vitro Cell Culture And In Situ Experiments Wednesday 14:50-16:20 |
II-30 Sathej Gopalakrishnan Towards assessing therapy failure in HIV disease: estimating in vivo fitness characteristics of viral mutants by an integrated statistical-mechanistic approach Wednesday 14:50-16:20 |
II-47 Alvaro Janda Application of optimal control methods to achieve multiple therapeutic objectives: Optimization of drug delivery in a mechanistic PK/PD system Wednesday 14:50-16:20 |
II-60 Ron Keizer cPirana: command-line user interface for NONMEM and PsN Wednesday 14:50-16:20 |
II-62 Gilbert Koch Solution and implementation of distributed lifespan models Wednesday 14:50-16:20 |
III-03 Elke Krekels Item response theory for the analysis of the placebo effect in Phase 3 studies of schizophrenia Thursday 10:05-11:35 |
III-13 Joanna Lewis A homeostatic model for CD4 count recovery in HIV-infected children Thursday 10:05-11:35 |
III-48 Lisa O'Brien Implementation of a Global NONMEM Modeling Environment Thursday 10:05-11:35 |
IV-25 Karl Brendel How to deal properly with change-point model in NONMEM? Thursday 14:55-16:20 |
IV-26 Frances Brightman Predicting Torsades de Pointes risk from data generated via high-throughput screening Thursday 14:55-16:20 |
IV-49 Teresa Collins Performance of Sequential methods under Pre-clinical Study Conditions Thursday 14:55-16:20 |
IV-54 Zeinab Daher Abdi Analysis of the relationship between Mycophenolic acid (MPA) exposure and anemia using three approaches: logistic regression based on Generalized Linear Mixed Models (GLMM) or on Generalized Estimating Equations (GEE) and Markov mixed-effects model. Thursday 14:55-16:20 |
IV-61 Cheikh Diack An indirect response model with modulated input rate to characterize the dynamics of Aβ-40 in cerebrospinal fluid Thursday 14:55-16:20 |
IV-63 Christian Diedrich Using Bayesian-PBPK Modeling for Assessment of Inter-Individual Variability and Subgroup Stratification Thursday 14:55-16:20 |